Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 3/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | CRYAA | P02489 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.37 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21903498 | 0.90 | TYR (0.47) | TYRSRCCA12CA1CA2 | |
| SCHEMBL30112151 | 0.90 | TYR (0.47) | TYRSRCCA12CA1CA2 | |
| SCHEMBL10378646 | 0.81 | TSHR (0.55) | CYSLTR2CYSLTR1 | |
| SCHEMBL3239754 | 0.80 | TYR (0.50) | TYRCA12CA1CA2CA7 | |
| SCHEMBL469144 | 0.80 | TYR (0.49) | TYRSRCHTTKDM4E | |
| SCHEMBL71452 | 0.80 | TYR (0.49) | TYRSRCHTT | |
| SCHEMBL30112103 | 0.79 | MEN1 (0.43) | TYRSRCCA12CA1CA2 | |
| SCHEMBL20576228 | 0.79 | MEN1 (0.43) | TYRSRCCA12CA1CA2 | |
| SCHEMBL20576405 | 0.79 | TYR (0.40) | TYRSRCKDM4E | |
| SCHEMBL29712429 | 0.79 | TYR (0.40) | TYRSRCKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3390343-B1 | RESORCINOL DERIVATIVES FOR COSMETIC USE THEREOF | OREAL (FR) | 2020-10-14 | — | — | EP | claimed |
| US-7541454-B2 | Compounds and methods for fluorescent labeling | EPOCH BIOSCIENCES, INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-20050159606-A1 | Compounds and methods for fluorescent labeling | EPOCH BIOSCIENCES, INC. (US) | 2005-07-21 | — | — | US | disclosed |
| WO-2005040357-A2 | COMPOUNDS AND METHODS FOR FLUORESCENT LABELING | EPOCH BIOSCIENCES, INC. (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159606-A1 | Compounds and methods for fluorescent labeling | TFEB, HLCS, PFAS | TYR 1222/4885SRC 3554/4885CRYAA 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.